S. P. Hunger, C. G. Mullighan, H. Dombret, T. Cluzeau, and F. Huguet, Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine, Curr Hematol Malig Rep, vol.125, pp.158-164, 2014.

F. Huguet, T. Leguay, and E. Raffoux, Pediatricinspired therapy in adults with Philadelphia chromosomenegative acute lymphoblastic leukemia: The GRAALL-2003 study, J Clin Oncol, vol.27, p.2574, 2009.

H. Kantarjian, D. Thomas, and S. O'brien, Longterm follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia, Cancer, vol.101, pp.2788-2801, 2004.

S. Maury, S. Chevret, and X. Thomas, Rituximab in B-lineage adult acute lymphoblastic leukemia, N Engl J Med, vol.375, pp.1044-1053, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812704

M. Lafage-pochitaloff, L. Baranger, and M. Hunault, Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia, Blood, vol.130, pp.1832-1844, 2017.

A. V. Moorman, C. J. Harrison, and G. A. Buck, Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial, Blood, vol.109, pp.3189-3197, 2007.

K. Beldjord, S. Chevret, and V. Asnafi, Oncoge, vol.123, pp.3739-3749, 2014.

N. Dhédin, A. Huynh, and S. Maury, Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia, Blood, vol.125, pp.2486-2496, 2015.

E. L. Kaplan and P. Meier, Non parametric estimation from incomplete observations, J Am Stat Assoc, vol.53, pp.457-481, 1958.

C. Cox, Multinomial regression models based on continuation ratios, Stat Med, vol.7, pp.435-441, 1988.

J. M. Rowe, G. Buck, and A. K. Burnett, Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993, all patients: Final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993), vol.106, pp.1827-1833, 2005.

R. Bassan, O. Spinelli, and E. Oldani, Improved lymphoblastic leukemia (ALL), Blood, vol.113, pp.4153-4162, 2009.

N. Gökbuget, J. Beck, and K. Brandt, Significant ALL (GMALL), Blood, vol.122, 2013.

N. Gökbuget, M. Kneba, and T. Raff, Prevention and management of asparaginase/ pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel, Leuk Lymphoma, vol.120, pp.526-534, 2015.

J. M. Storring, M. D. Minden, and S. Kao, Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

, Br J Haematol, vol.146, pp.76-85, 2009.

D. Douer, I. Aldoss, and M. A. Lunning, Clin Oncol, vol.32, pp.905-911, 2016.

C. Orvain, M. Balsat, and V. Lhéritier, , 2016.

C. Mariette, E. Tavernier, and D. Hocquet, Inotuzuab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): Interim result of a phase II clinical trial, Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: A GRAALL-2005 study, vol.58, pp.3660-3668, 2016.

. Affiliations,

F. Huguet and E. Delabesse, AP-HP

A. Buzyn and V. Asnafi,

U. Paris-descartes, P. Leguay, C. Hospitalier-universitaire, P. Thomas, and V. Lhéritier,

M. Escoffre-barbe,

P. Chevallier and M. C. Béné,

M. Hunault and N. Ifrah, Angers

S. Lepretre, H. Centre, R. Becquerel, and . Marolleau,